Review Article

Recent advances in the genetics of osteoporosis

F.M.K. Williams and T.D. Spector

Twin Research and Genetic Epidemiology Unit, St Thomas' Hospital, London, UK

Abstract

It has been known for over 20 years that osteoporosis is highly influenced by genetic factors. Bone mineral density (BMD) has also been shown to be highly heritable. Other known risk factors for osteoporotic fractures such as reduced bone quality, femoral neck geometry and bone turnover are now also known to be heritable. Susceptibility to osteoporosis is mediated, in all likelihood, by multiple genes each having small effect. Different approaches are being used currently to identify the many genes responsible. These include linkage studies in man and experimental animals as well as candidate gene studies and alterations in gene expression. Linkage studies have identified multiple quantitative trait loci (QTL) for regulation of BMD and, with twin studies, have indicated that the effects of these loci are partly site-dependent and sex-specific. On the whole, the genes responsible for BMD regulation at these QTL have not yet been isolated. Most studies have used the candidate gene approach. The vitamin D receptor gene (VDR), the collagen type I alpha 1 gene (COLIA1) and estrogen receptor gene (ER) alpha have been most widely investigated and found to play a role in regulating BMD, but the effects are modest and together probably account for less than 5% of the heritable contribution to BMD. Genes may vary in their influence of particular intermediate phenotypes, and we now know that not all genes influencing BMD will be important in fracture. In addition, the study of other diseases such as osteoarthritis and metabolic bone syndromes may prove fruitful in highlighting genes which overlap to osteoporosis as well. As large scale genetic testing becomes more cost-effective, recent findings have illustrated the potential of novel approaches. These include combining large multi-national populations for candidate gene analysis, meta-analyses, DNA pooling studies and gene expression studies.

Keywords: Osteoporosis, Genes, Heritable, Bone Mineral Density, Twin

Osteoporosis genes and their identification

Osteoporosis is a skeletal condition characterized by diminished bone mineral density and deterioration in bone microarchitecture. The main clinical end point is fracture. It is common and costly, both financially and in social terms. Genetic factors have long been recognised to play an important role in both osteoporosis and its associated phenotypes, including bone mineral density (BMD), bone mass, broadband ultrasound attenuation (BUA), velocity of sound (VOS), to name but a few. Twin and family studies have estimated that 50-85% of the variance in bone mass is genetically determined[1-4]. Similar studies have shown evidence of significant genetic effects on other determinants of fracture risk, including quantitative ultrasound properties of bone[5], several aspects of femoral neck geometry[5], muscle strength[6], bone turnover markers[7,8], body mass index[9] and age at menopause[10].

Unfortunately, there are few data describing the heritability of osteoporotic fracture, mainly because recruiting adequate numbers of study subjects is difficult and expensive. Several studies have shown that a family history of fracture is a risk factor for fracture, independent of BMD[11-14]. One small twin study from Finland found identical twins to have only slightly higher rates of concordance for fracture than non-identical twins[15], suggesting that environmental factors are more important than genetic ones. This illustrates the important difference between associated phenotypes, osteoporosis and fracture: associated phenotypes have been found to be highly heritable but finding the genes responsible does not necessarily identify genes for other associated phenotypes or genes influencing the clinically important end point, fracture. Another such example

is that of genes influencing bone density and wrist fracture. A larger UK twin study than previously performed recently reported both wrist BMD and wrist fracture to be independently heritable. However, only a modest genetic overlap was found between genes influencing BMD/VOS properties of bone and genes influencing fracture[16].

Several approaches are being employed currently in the search for genes which contribute to osteoporosis in the general population (reviewed by Huang et al.[17]). Rare monogenic conditions affecting bone have already been used to cast light on genes which may influence population osteoporosis. Going forward, the most important approaches include candidate gene association studies and linkage studies. All three approaches are discussed below.

Genes of rare monogenic diseases

Osteoporosis and fragility fractures are features of several rare monogenic diseases, and provide an obvious place to start the search for genes influencing osteoporosis in the general population. Such conditions are not always informative, however. They include osteogenesis imperfecta (OI), the osteoporosis-pseudoglioma syndrome (OPS) and syndromes associated with inactivating mutations of the estrogen receptor alpha and aromatase genes.

OI describes a heterogeneous group of monogenic disorders characterized by multiple bone fractures which, in most forms, is caused by mutations in the type I collagen genes COLIA1 and COLIA2. The genes which encode type I collagen possess mutations in many different places, accounting for the heterogenous nature of the disorder – from mild to extremely severe. OPS is a rare, autosomal recessive disorder characterized by juvenile onset osteoporosis and blindness due to persistent vascularisation of the eye. Initial linkage studies mapped OPS to chromosome 11q12-13[18]. Subsequent work showed the disease to be caused by inactivating mutations in the low density lipoprotein-related receptor-5 (Lrp-5)[19]. Another phenotype, autosomal dominant highbone-mass, maps to the same region[20] and independently was reported to be caused by an activating mutation of the same receptor[21]. Osteoporosis has been reported in association with homozygous inactivating mutations of the estrogen receptor and aromatase genes, emphasising the importance of estrogen in the attainment and maintenance of peak bone mass. Mutations in the latency-activating peptide (LAP) domain of the TGF beta 1 gene are associated with Camurati-Engelmann disease – a condition characterized by increased BMD in the diaphysis of long bones[22]. Mutations of the TCIRG1 gene, which encodes a sub-unit of the osteoclast proton pump, have been shown responsible for the autosomal recessive condition osteopetrosis[23].

The important question is do the genetic clues obtained from rare diseases cast any light on the osteoporosis and fractures seen in the normal population? There is evidence that some of these genes do contribute to regulation of 'normal' BMD. For example, LRP gene polymorphisms have recently been shown

Devoto et al. (1998)	1p36	3.51	Hip BMD
	2p23	2.29	Hip BMD
	4q33	2.95	Hip BMD
Nui et al. (1999)	2p21	2.15	Wrist BMD
Koller et al. (2000)	1q21	3.86	Spine BMD
	5q33	2.23	Hip BMD
Karasik 2002	6p21	2.93	Spine BMD
	21q22	3.14	Hip BMD
Wilson 2003	3p21	2.7	Spine BMD
	1p36	2.4	Hip BMD
Iceland 2003	20p12	3.18	Hip BMD
	20p12	2.89	Spine BMD

Table 1. Summary of main quantitative trait loci findings for BMD in humans.

to be associated with bone mineral content, bone area and stature particularly in males[24]. Several groups have reported polymorphisms in the TGF beta gene to be associated with BMD and osteoporotic fracture[25,26] and polymorphisms of the TCIRG1 genes (sub-unit of osteoclast proton pump) have been found to be associated with BMD in normal subjects[27].

Other methods of identifying genes in osteoporosis

Linkage studies

Linkage disequilibrium (LD) refers to the phenomenon whereby genes lying close together tend to be inherited together. Evidence suggests that LD varies greatly and variably according to both chromosomal region and human population studied, but can extend to 350Kb or further[28]. Linkage studies are a well validated method for the identification of genes responsible for monogenic diseases and have been applied to the identification of chromosomal regions which harbour genes regulating quantitative traits such as bone mass, in so-called QTL. An advantage of linkage-based studies is that they offer the prospect of identifying new molecular pathways that regulate bone metabolism. In addition they are not influenced by population admixture. One disadvantage is that they have low statistical power to detect genes having modest effects on BMD and hence require family samples of considerable size (several thousand) as well as an independent validation group.

Linkage studies in animals

Linkage studies in experimental animals have also been used in the identification of genes responsible for complex traits. This approach has several advantages: optimal control over the environment can be exercised minimising the influence of confounding factors; and large numbers of progeny may be generated. The latter provides excellent statistical power. In addition,

fine mapping of loci identified may be achieved using a technique known as 'back crossing'. The most obvious drawback of the approach is that genes/loci regulating BMD in mice may not be influential in regulating BMD in man.

A recent study has combined genetic and genomic approaches in mice to provide evidence of a role for the *Alox15* gene. Previous studies by the same group had identified a region on mouse chromosome 11 as influencing peak BMD[29]. In the recent work, a congenic mouse model was constructed using the area of interest on chromosome 11 and shown to have increased BMD[30]. Microarray analysis identified *Alox15* as the differentially expressed gene which encodes 12/15 lipoxygenase (12/15-LO), and other studies confirmed that this overexpression had biological impact (increased expression of CD36 and reduced osteocalcin). A 12/15-LO knock-out mouse model also confirmed the findings, as did pharmacological inhibitors of 15-lipoxygenase[30]. Work in humans has also shown linkage to a region on human chromosome 17 containing the genes for 12 and 15 lipoxygenase, suggesting that the findings in mice may be of direct relevance to human BMD regulation[31].

Linkage studies in humans

Linkage studies in sib-pairs and extended families having osteoporosis have also been used to identify loci linked to BMD. Early studies identified loci on chromosomes 1p36, 2p23-p24 and 4q32-34[31], with subsequent work in a second sample confirming linkage to the 1p36 locus[32]. A genome-wide search in a Chinese sample for loci regulating forearm BMD[33] also revealed the highest LOD score at 2p23-24. Koller and co-workers conducted a whole genome search in a series of 595 healthy Caucasian and African American female sib-pairs, finding LOD = +3.86 at chromosome 1q21-23[34] and an area suggestive of linkage at 5q33-35. Linkage studies in the same population identified multiple loci for regulation of femoral neck geometry on chromosome 5q and 4q and 17q[35]. Karasik and colleagues[36] have reported a genome scan on 330 families (Framingham Study) and identified several QTL suggestive of linkage on chromosome 6 and 20. Of interest, a subsequent analysis using the same population suggested that QTL regulation of BMD differs between men and women, and different QTL were found for the phenotypes peak bone mass and bone loss[37]. More recently, Wilson et al. have performed one of the largest linkage studies with 1,100 dizygous UK twin pairs, defining two regions of suggestive linkage on chromosomes 1p36 and 3p21. Linkage to the 3p21 region was confirmed in a validation sample of 254 extreme discordant or concordant affected sib pairs having low BMD[38].

Most linkage studies have examined BMD as the associated phenotype of interest. However, in a recent study of Icelandic families, Styrkasdottir and colleagues detected significant linkage (LOD = 5.1) of osteoporosis to chromosome 20p12 using a novel classification system[39]. In this study, subjects were scored as "affected" if they had reduced BMD (Z-score less than − 1.0 at spine or hip) or if they had a history of fragility fractures, or if they were undergoing bisphosphonate treatment for osteoporosis. The Icelandic study also suggested linkage of spine and hip BMD to chromosome 20p12, with LOD scores of around +3.0 on the genome-wide scan and LOD scores of between +3.4 and +4.0 on fine mapping. Further analysis showed that part of the linkage signal was due to an association between osteoporosis and a polymorphism in the BMP2 gene which results in a serine-alanine amino acid change at codon 37.

Associated osteoporosis risk phenotypes other than BMD have also been examined. Using ultrasound to generate two associated phenotypes, BUA and VOS, Wilson et al. have performed a genome-wide screen of dizygous twin pairs using 737 highly polymorphic microsatellite markers. Evidence was found of linkage to chromosome 2q33-37 (BUA, LOD 2.1-5.1) and 4q12-21 (VOS, LOD2.2-3.4). LOD scores >2 were also identified on chromosomes 1,2,13,14 and X[40]. Similar work on the Framingham Study sample showed quantitative ultrasound to be linked to chromosomal regions 1p36.1[41]. Subsequently, this group has used combined bone phenotypes to see if more information may be obtained. Using BMD and quantitative ultrasound, they performed principal components analyses: linkage to 1q21.3 and 8q24.3 was found with the first prinicipal component (LODs 2.5, 2.4) while 1p36 was found with the second (LOD 2.1)[42].

Biochemical markers of bone turnover have previously been shown to be heritable and have recently been the subject of a large twin study[43]. A genome-wide scan was performed on levels of markers of bone formation (alkaline phosphatase, osteocalcin), bone resorption (urinary deoxypyridinoline corrected for urine creatinine) and calcium metabolism (parathyroid hormone). This revealed an area of significant linkage (LOD=3.9) on chromosome 1 and area of suggestive linkage on chromosome 4 (LOD=2.5). Of particular interest, the QTL on chromosome 1 had pleiotropic effects, acting to lower urinary deoxypyridinoline and increase serum parathyroid hormone. This study of 932 non-identical female twin pairs has the advantage over other sib-pairs of matching for age and sex – both important factors in bone metabolism/osteoporosis.

Given the polygenic nature of BMD regulation and osteoporosis susceptibility, most linkage studies performed to date have probably been underpowered, although the two large studies mentioned each included over 1,000 subjects[38,39]. Overall, results from different linkage studies show more discrepancy than agreement, probably because of the effects of differing study populations and differing criteria for subject enrolment. It is partly for these reasons and easier access to clinical samples that association studies are becoming more widely used.

Candidate gene studies

Candidate gene studies are the most widely used method in use at present. Candidate gene association studies are rel-

atively easy to perform and may have sufficient power to detect small allelic effects. They may be disadvantaged, however, by the effects of confounding factors, genetic hereogeneity and population stratification. Furthermore, demonstration of an association between a candidate gene and BMD does not necessarily mean that the gene is causally responsible for the effect observed, as there may be linkage disequilibrium with a nearby causal gene. The transmission desequilibrium test (TDT) can help by testing candidate genes for both association and linkage.

Candidate genes investigated thus far have included genes influencing cytokines and growth factors which regulate bone turnover; genes that encode components of bone matrix; and genes that encode receptors for calciotropic hormones. Individual candidate genes that have been implicated in the regulation of bone mass or osteoporotic fractures have been reviewed elsewhere[44]. Recent advances in knowledge are discussed in more detail below.

Vitamin D receptor (VDR)

Vitamin D interacts with its receptor to play an important role in calcium homeostasis by regulating bone cell growth and differentiation, intestinal calcium absorption and parathyroid hormone secretion. The VDR was therefore a natural place to begin looking for genetic variation that might account for osteoporosis. The original finding that VDR alleles played a role in BMD is now over 10 years old[45]. Other studies of VDR in relation to bone mass have since been conflicting, and it is likely that the VDR genotype is associated with relatively modest effects on bone mass. Of interest, the relationship between VDR genotype and BMD is thought to be modulated by both calcium intake and vitamin D intake. Various different polymorphisms have been described, in different populations[46,47], although the mechanisms by which these polymorphisms modulate VDR function remain unclear. Some 3' polymorphisms may influence RNA stability, and isoforms of VDR encoded by different alleles may possess different functions[46]. In addition there are data to suggest that an interaction between 5' and 3' polymorphisms is involved in regulating VDR function.

Type I collagen

The genes encoding type I collagen (COLIA1 and COLIA2) are important, well-studied candidates for the pathogenesis of osteoporosis. A common polymorphism affecting the transcription factor Sp1 binding site has been shown to have increased prevalence in osteoporosis patients[48]. Positive associations between the COLIA1 Sp1 polymorphism and bone mass or osteoporotic fractures were subsequently reported in several populations, and meta-analysis also supported the COLIA1 genotype conferring differences in BMD[49]. Ethnic differences have been reported in population prevalence of COLIA1 Sp1 alleles with the polymorphism being common in Caucasian populations, but rare in Africans and the Chinese[50]. Overall the data suggest that the COLIA1 Sp1 polymorphism is a functional variant which has adverse effects on bone composition and mechanical strength. Haplotype analysis has shown that susceptibility to fracture is driven by the Sp1 polymorphism rather than other known polymorphisms at the COLIA1 locus[51], although it remains possible that hitherto unidentified polymorphisms in linkage disequilibrium with the Sp1 polymorphism exist and contribute to the observed effects. From a clinical viewpoint, the COLIA1 polymorphism may be of value not as a therapeutic target but as a marker of osteoporotic fracture risk, since it predicts fractures independent of BMD and interacts with BMD to enhance fracture prediction[52].

Estrogen receptors and aromatase genes

In view of the strong relationship between estrogen deficiency and bone loss, the estrogen receptor alpha (ER) gene has long been a strong candidate gene for osteoporosis. An association has been reported between a TA repeat polymorphism in the ER promoter and bone mass in both Japanese and US populations. Other investigators have reported positive associations between haplotypes defined by PvuII and XbaI polymorphisms in intron 1 of the ER gene and bone mass[53] as well as age at menopause[54]. The molecular mechanism by which these polymorphisms influence bone mass are as yet unclear, but a meta-analysis of the intron 1 polymorphisms indicated that the association with BMD and fracture is attributable mainly to variation at the XbaI site[55]. More recently, a large-scale study comprising 8 European centres has attempted to answer the question more definitively using almost 19,000 subjects. Three common ER gene polymorphisms were studied and none of the polymorphisms was shown to be associated with BMD. The absence of a Xba1 polymorphism recognition site conferred a risk reduction in all fractures of 19% while the risk reduction for vertebral fractures was 35%. The effects on fracture were independent of BMD. Polymorphisms in PvuII and TA repeats did not appear to have any influence[56].

Aromatase is the enzyme which converts androgens into estrogens so is likely to be of importance in bone metabolism in men and postmenopausal women. It is encoded by the CYP19 gene. A recent study from Australia has shown the TTTA repeat polymorphism of CYP19 to be associated with higher circulating estradiol, higher BMD at hip and lumbar spine and lower markers of bone turnover, in over 1,200 women age 70 years or older[57]. Similar findings have also been reported in elderly Italian men[58].

Other genes

Polymorphisms in several other candidate genes have been associated with bone mass and/or osteoporotic fracture including TGFβ-1 and the IL-6 locus. The effects of these polymorphisms on IL-6 function are yet to be determined. Two studies have looked at the possible associations

between apolipoprotein E (APOE) alleles and osteoporosis but again the mechanisms by which APOE alleles influence susceptibility to osteoporosis remain unclear. Two groups have reported an association between a coding polymorphism of the calcitonin receptor gene and BMD. The osteocalcin gene has been found to be associated and linked to BMD and bone quality[59]. Other candidate genes which have been studied in relation to BMD include; parathyroid hormone, the androgen receptor, aromatase, osteoprotegerin, Klotho and the interleukin-1 receptor antagonist (IL-1ra). Most of the original findings associated with these genes have not been consistently replicated.

In addition to the study of single genes or polymorphisms in isolation, it has been realized that both gene-gene and gene-environment interactions play an important role in influencing the variation of expression of complex traits such as osteoporosis within populations. Such interactions are discussed below.

Gene-gene and gene-environment interactions

A Dutch study of 1,000 postmenopausal women looked at the effects of a combination of both the G to A polymorphism in the COL1A1 Sp1 binding site and the 'baT' haplotype of VDR. They found that there was a significant interaction between the genotypes, both being independent of the effect of BMD[60]. The Danish Osteoporosis Prevention Study has recently reported the influence of polymorphisms within the CYP19 and androgen receptor genes in almost 1,800 newly postmenopausal women who were randomized to receive estrogen replacement therapy or no treatment[61]. While perimenopausal bone loss was not associated with either genes' polymorphisms, the BMD response over 5 years to estrogen was influenced by genotype: one CYP19 allele was associated with significantly greater response. While the androgen receptor genotype was not related to BMD, a modifying effect of sex hormone-binding globulin (SHBG) was observed. Thus in the highest quartile of SHBG, androgen receptor genotype was associated with baseline BMD.

These types of study emphasize the importance of both gene-gene and gene-environment interactions and highlight once again the need for large, usually multi-center, studies to recruit sufficient subjects to enable well-powered studies to be performed. They also create new difficulties of their own, particularly problems associated with multiple testing of subgroups, which unless taken into account in the analysis increase the likelihood of spurious positive findings.

Gene Expression Studies

A novel approach to the question of osteoporosis genes is that involving gene expression studies. In this type of study, differences in gene expression are explored in tissues derived from subjects expressing and not expressing the trait of interest. Very much greater power is obtained if the genetic background of the trait-discordant subjects is similar or the same, as in the case of identical twins. One such small study has used osteoblast-like culture from 2 pairs of monozygotic twins discordant for BMD and one concordant pair. Genome-wide gene expression of the cell culture derived from bone marrow aspirates suggests the following genes were differentially expressed: chondroitin beta 1,4 N-acetyl-galactosaminyltransferase, inhibin beta A, interleukin-1 beta and colony stimulating factor 1 macrophage[62]. These genes are known to play a part in bone physiology. Although the numbers studied were small this study highlights both the potential of the emerging new technology for examining gene expression and the further benefits that may be derived from the twin registers around the world in providing informative willing subjects for intensive study.

Pooling studies

Another newer method being used for increasing the power and cost-effectiveness of studies to detect genes associated with osteoporosis is that of pooling. This type of association study contrasts DNA pools from 200-300 subjects with and without the trait of interest, for example BMD. One such study has used 25,000 SNPs in 16,000 genes from women divided into study groups by expression of the traits high and low BMD. Because of the loss of power with multiple testing, the findings were verified by individual genotyping in two further case control groups. The differences in allele frequency between the two trait expression groups suggested a candidate locus in the phosphodiesterase 4D gene (PDE4D) gene on chromosome 5q12. This was fine mapped using 80 SNPs within 50 kB of the marker SNP[63]. This study also produced evidence in support of the association with the Ser37Val polymorphism in BMP2, a gene known to interact with PDE4D (and implicated in Icelandic studies). These data illustrate the potential of these methods but also highlight the need for several replication groups.

Overlapping phenotypes

In addition to the associated phenotypes and traits which may be used as surrogates of the main clinical outcome of interest, other bone diseases may also shed light on genes of importance in osteoporosis. Studies have shown that perhaps 30% of genes involved in bone metabolism overlap with those influencing osteoarthritis – a disease of bone as well as cartilage. Genes believed to be common to both include the VDR, the COLIA1 and possibly the ER genes[64]. A recent example of an association study of OA progression by Valdes et al. implicated several bone genes such as BMP2[65] and genes involved in inflammation and cytokines have been found, somewhat surprisingly, to be associated with chronic diseases such as disc degeneration[66]. With the finding that the LRP-5 gene is associated with osteoporosis comes the realization that genes controlling pathways such as lipid metabolism and inflammation may be important in what

were considered non-inflammatory bone conditions. Thus, the choice of potential candidate genes is getting considerably larger and genetic researchers have increasingly to cross the traditional disease boundaries.

Future work

What direction is work into identification of osteoporosis genes likely to take in the future? At present, some argue, lines of investigation are driven by technology and the availability of new assay techniques handling ever larger numbers of polymorphisms. Although the estimated number of human genes continues to fall (currently around 23,000) the number of recognized SNPs increases – with over 30,000 known non-synonymous SNPs and the possibilty of testing samples with over 250,000 validated SNPs at a cost of less than 1 US cent per SNP. The new technology will enable increasingly large panels of polymorphisms, as well as gene expression levels and, eventually, proteins and metabolic profiles to be studied simultaneously. Funding for future work should be prioritised for those study proposals demonstrating sufficient power to answer the question being addressed, although the increasing problem of multiple testing and the difficulties in having large numbers of replicate clinical cohorts will make the task no less challenging.

In conclusion, osteoporosis is a perfect example of a complex genetic trait. The associated phenotypes studied thus far have heritabilities of 50-80% and a large number of genes are likely to be involved in its pathogenesis. Several candidate genes have been identified but their individual effects are small. Many genome-wide linkage scans have been performed but the results are inconsistent – underlining some of the difficulties in pinpointing the genes – and suggest that to maximise the chances of gene discovery a full range of phenotypes and methods will need to be utilised. Regardless of the methods employed, combining data sets will be essential to obtain sufficient power. This means national and international collaboration will play a vital role in taking forward the work done so far.

References

1. Pocock NA, Eisman JA, Hopper JL, Yeates MG, Sambrook PN, Eberl S. Genetic determinants of bone mass in adults: a twin study. J Clin Invest 1987; 80:706-710.
2. Smith DM, Nance WE, Kang KW, Christian JC, Johnston CC. Genetic factors in determining bone mass. J Clin Invest 1973; 52:2800-2808.
3. Gueguen R, Jouanny P, Guillemin F, Kuntz C, Pourel J, Siest G. Segregation analysis and variance components analysis of bone mineral density in healthy families. J Bone Miner Res 1995; 12:2017-2022.
4. Krall EA, Dawson-Hughes B. Heritable and life-style determinants of bone mineral density. J Bone Miner Res 1993; 8:1-9.
5. Arden NK, Baker J, Hogg C, Baan K, Spector TD. The heritability of bone mineral density, ultrasound of the calcaneus and hip axis length: a study of postmenopausal twins. J Bone Miner Res 1996; 11:53053-53054.
6. Arden NK, Spector TD. Genetic influences on muscle strength, lean body mass, and bone mineral density: a twin study. J Bone Miner Res 1997; 12:2076-2081.
7. Hunter D, de Lange M, Snieder H, MacGregor AJ, Swaminathan R, Thakker RV, Spector TD. Genetic contribution to bone metabolism, calcium excretion, and vitamin D and parathyroid hormone regulation. J Bone Miner Res 2001; 16:371-378.
8. Garnero P, Arden NK, Griffiths G, Delmas PD, Spector TD. Genetic influence on bone turnover in postmenopausal twins. J Clin Endocrinol Metabol 1996; 81:140-146.
9. Kaprio J, Rimpela A, Winter T, Viken RJ, Rimpela M, Rose RJ. Common genetic influences on BMI and age at menarche. Hum Biol 1995; 67:739-753.
10. Snieder H, MacGregor AJ, Spector TD. Genes control the cessation of a woman's reproductive life: a twin study of hysterectomy and age at menopause. J Clin Endocrinol Metab 1998; 83:1875-1880.
11. Torgerson DJ, Campbell MK, Thomas RE, Reid DM. Prediction of perimenopausal fractures by bone mineral density and other risk factors. J Bone Miner Res 1996; 11:293-297.
12. Cummings SR, Nevitt MC, Browner WS, Stone K, Fox KM, Ensrud KE, Cauley J, Black D, Vogt TM. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med 1995; 332:767-773.
13. Keen RW, Hart DJ, Arden NK, Doyle DV, Spector TD. Family history of appendicular fracture and risk of osteoporosis: a population-based study. Osteoporos Int 1999; 10:161-166.
14. Deng HW, Chen WM, Recker S, Stegman MR, Li JL, Davies KM, Zhou Y, Deng H, Heaney R, Recker RR. Genetic determination of Colles' fracture and differential bone mass in women with and without Colles' fracture. J Bone Miner Res 2000; 15:1243-1252.
15. Kannus P, Palvanen M, Kaprio J, Parkkari J, Koskenvuo M. Genetic factors and osteoporotic fractures in elderly people: prospective 25-year follow-up of a nationwide cohort of elderly Finnish twins. BMJ 1999; 319:1334-1337.
16. Knapp KM, Andrew T, MacGregor AJ, Blake GM, Fogelman I, Spector TD. An investigation of unique and shared gene effects on speed of sound and bone density using axial transmission quantitative ultrasound and DXA in twins. J Bone Miner Res 2003; 18:1525-1530.
17. Huang Q-Y, Recker RR, Deng H-W. Searching for osteoporosis genes in the post-genome era: progress and challenges. Osteoporos Int 2003; 14:701-715.
18. Gong Y, Vikkula M, Boon L, Liu J, Beighton P, Ramesar R, et al. Osteoporosis-pseudoglioma syndrome, a

disorder affecting skeletal strength and vision, is assigned to chromosome region 11q12-13. Am J Hum Genet 1998; 1996:146-151.

19. Gong Y, Slee RB, Fukai N, Rawadi G, Roman-Roman S, Reginato AM, et al. Osteoporosis-Pseudoglioma Syndrome Collaborative Group. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 2001; 107:513-523.

20. Johnson ML, Gong G, Kimberling W, Recker SM, Kimmel DB, Recker RR. Linkage of a gene causing high bone mass to human chromosome 11 (11q12-13). Am J Hum Genet 1997; 60:1326-1332.

21. Little RD, Carulli JP, Del Mastro RG, Dupuis J, Osborne M, Folz C, et al. A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet 2002; 70:11-19.

22. Janssens K, Gershoni-Baruch R, Guanabens N, Migone N, Ralston S, Bonduelle M, Lissens W, Van Maldergem L, Vanhoenacker F, Verbruggen L, Van Hul W. Mutations in the gene encoding the latency-associated peptide of TGF-β 1 cause Camurati-Engelmann disease. Nat Genet 2000; 26:273-275.

23. Sobacchi C, Frattini A, Orchard P, Porras O, Tezcan I, Andolina M, et al. The mutational spectrum of human malignant autosomal recessive osteopetrosis. Hum Mol Genet 2001; 10:1767-1773.

24. Ferrari SL, Deutsch S, Choudhury U, Chevalley T, Bonjour JP, Dermitzakis ET, Rizzoli R, Antonarakis SE. Polymorphisms in the low-density lipoprotein receptor-related protein-5 (LRP5) gene are associated with variation in vertebral bone mass, vertebral bone size and stature in whites. Am J Hum Genet 2004; 74:866-875.

25. Langdahl BL, Carstens M, Stenkjaer L, Eriksen EF. Polymorphisms in the transforming growth factor beta 1 gene and osteoporosis. Bone 2003; 32:297-310.

26. Keen RW, Snieder H, Molloy H, Daniels J, Chiano M, Gibson F, Fairbairn L, Smith P, MacGregor AJ, Gewert D, Spector TD. Evidence of association and linkage disequilibrium between a novel polymorphism in the transforming growth factor beta 1 gene and hip bone mineral density: a study of female twins. Rheumatology (Oxford) 2001; 40:48-54.

27. Sobacchi C, Vezzoni P, Reid DM, McGuigan FE, Frattini A, Mirolo M, Albhaga OM, Musio A, Villa A, Ralston SH. Association between a polymorphism affecting an AP1 binding site in the promoter of the TCIRG1 gene and bone mass in women. Calcif Tissue Int 2004; 74:35-41.

28. Reich DE, Cargill M, Bolk S, Ireland J, Sabeti PC, Richter DJ, Lavery T, Kouyoumjian R, Farhadian SF, Ward R, Lander ES. Linkage disequilibrium in the human genome. Nature 2001; 411:199-204.

29. Klein RF, Mitchell SR, Phillips TJ, Belknap JK, Orwoll ES. Genetic analysis of bone mass in mice. J Bone Miner Res 1998; 13:1648-1656.

30. Klein RF, Allard J, Avnur Z, Nikolcheva T, Rotstein D, Carlos AS, Shea M, Waters RV, Belknap JK, Peltz G, Orwoll ES. Regulation of bone mass in mice by the lipoxygenase gene Alox15. Science 2004; 303:229-232.

31. Devoto M, Shimoya K, Caminis J, Ott J, Tenenhouse A, Whyte MP, Sereda L, Hall S, Considine E, Williams CJ, Tromp G, Kuivaniemi H, Ala-Kokko L, Prockop DJ, Spotila LD. First-stage autosomal genome screen in extended pedigrees suggests genes predisposing to low bone mineral density on chromosomes 1p, 2p and 4q. Eur J Hum Genet 1998; 6:151-157.

32. Devoto M, Specchia C, Li HH, Caminis J, Tenenhouse A, Rodriguez H, Spotila LD. Variance component linkage analysis indicates a QTL for femoral neck bone mineral density on chromosome 1p36. Hum Mol Genet 2001; 10:2447-2452.

33. Nui T, Chen C, Cordell H, Yang J, Wang B, Wang Z, Fang Z, Schork NJ, Rosen CJ, Xu X. A genome-wide scan for loci linked to forearm bone mineral density. Hum Genet 1999; 104:226-233.

34. Koller DL, Econs MJ, Morin PA, Christian JC, Hui SL, Parry P, Curran ME, Rodriguez LA, Conneally PM, Joslyn G, Peacock M, Johnston CC, Foroud T. Genome screen for QTLs contributing to normal variation in bone mineral density and osteoporosis. J Clin Endocrinol Metab 2000; 85:3116-3120.

35. Koller DL, Liu G, Econs MJ, Hui SL, Morin PA, Joslyn G, Rodriguez LA, Conneally PM, Christian JC, Johnston CC Jr, Foroud T, Peacock M. Genome screen for quantitative trait loci underlying normal variation in femoral structure. J Bone Miner Res 2001; 16:985-991.

36. Karasik D, Myers RH, Cupples LA, Hannan MT, Gagnon DR, Herbert A, Kiel DP. Genome screen for quantitative trait loci contributing to normal variation in bone mineral density: the Framingham Study. J Bone Miner Res 2002; 17:1718-1727.

37. Karasik D, Cupples LA, Hannan MT, Kiel DP. Age, gender, and body mass effects on quantitative trait loci for bone mineral density: the Framingham Study. Bone 2003; 33:308-316.

38. Wilson SG, Reed PW, Bansal A, Chiano M, Lindersson M, Langdown M, Prince RL, Thompson D, Thompson E, Bailey M, Kleyn PW, Sambrook P, Shi MM, Spector TD. Comparison of genome screens for two independent cohorts provides replication of suggestive linkage of bone mineral density to 3p21 and 1p36. Am J Hum Genet 2003; 72:144-155.

39. Styrkarsdottir U, Cazier JB, Kong A, Rolfsson O, Larsen H, Bjarnadottir E, Johannsdottir VD, Sigurdardottir MS, Bagger Y, Christiansen C, Reynisdottir I, Grant SF, Jonasson K, Frigge ML, Gulcher JR, Sigurdsson G, Stefansson K. Linkage of osteoporosis to chromosome 20p12 and association to BMP2. PLoS Biol 2003; 1:1-9.

40. Wilson SG, Reed PW, Andrew T, Barber MJ, Lindersson M, Langdown M, Thompson D, Thompson E, Bailey M,

Chiano M, Kleyn PW, Spector TD. A genome screen of a large twin cohort reveals linkage for quantitative ultrasound of the calcaneus to 2q33-37 and 4q12-21. J Bone Miner Res 2004; 19:270-277.

41. Karasik D, Myers RH, Hannan MT, Gagnon D, McLean RR, Cupples LA, Kiel DP. Mapping of quantitative ultrasound of the calcaneus bone to chromosome 1 by genome-wide linkage analysis. Osteoporos Int 2002; 13:796-802.

42. Karasik D, Cupples LA, Hannan MT, Kiel DP. Genome screen for a combined bone phenotype using principal component analysis: the Framingham Study. Bone 2004; 34:547-556.

43. Andrew T, Wilson S, Swaminathan R, Spector TD. A genome-wide screen for the genetic regulation of bone turnover and calcium metabolism in healthy dizygotic female twins shows evidence for linkage on chromosomes 1 and 4. J Bone Miner Res 2005 (in press).

44. Liu YZ, Liu YJ, Recker RR, Deng HW. Molecular studies of identification of genes for osteoporosis: the 2002 update. J Endocrinol 2003; 177:147-196.

45. Morrison NA, Qi JC, Tokita A, Kelly PJ, Crofts L, Nguyen TV, Sambrook PN, Eisman JA. Prediction of bone density from vitamin D receptor alleles. Nature 1994; 367:284-287.

46. Arai H, Miyamoto K-I, Taketani Y, Yamamoto H, Iemori Y, Morita K, Tonai T, Nishisho T, Mori S, Takeda E. A vitamin D receptor gene polymorphism in the translation initiation codon: effect on protein activity and relation to bone mineral density in Japanese women. J Bone Miner Res 1997; 12:915-921.

47. Arai H, Miyamoto KI, Yoshida M, Yamamoto H, Taketani Y, Morita K, Kubota M, Yoshida S, Ikeda M, Watabe F, Kanemasa Y, Takeda E. The polymorphism in the caudal-related homeodomain protein Cdx-2 binding element in the human vitamin D receptor gene. J Bone Miner Res 2001; 16:1256-1264.

48. Grant SF, Reid DM, Blake G, Herd R, Fogelman I, Ralston SH. Reduced bone density and osteoporosis associated with a polymorphic Sp1 binding site in the collagen type I alpha 1 gene. Nat Genet 1996; 14:203-205.

49. Mann V, Hobson EE, Li B, Stewart TL, Grant SF, Robins SP, Aspden RM, Ralston SH. A COL1A1 Sp1 binding site polymorphism predisposes to osteoporotic fracture by affecting bone density and quality. J Clin Invest 2001; 107:899-907.

50. Beavan S, Prentice A, Dibba B, Yan L, Cooper C, Ralston SH. Polymorphism of the collagen type I alpha 1 gene and ethnic differences in hip-fracture rates. N Engl J Med 1998; 339:351-352.

51. McGuigan FE, Reid DM, Ralston SH. Susceptibility to osteoporotic fracture is determined by allelic variation at the Sp1 site, rather than other polymorphic sites at the COLIA1 locus. Osteoporos Int 2000; 11:338-343.

52. McGuigan FEA, Armbrecht G, Smith R, Felsenberg D, Reid DM, Ralston SH. Prediction of osteoporotic fractures by bone densitometry and COLIA1 genotyping: a prospective, population-based study in men and women. Osteoporos Int 2001; 12:91-96.

53. Kobayashi S, Inoue S, Hosoi T, Ouchi Y, Shiraki M, Orimo H. Association of bone mineral density with polymorphism of the estrogen receptor gene. J Bone Miner Res 1996; 11:306-311.

54. Weel AE, Uitterlinden AG, Westendorp IC, Burger H, Schuit SC, Hofman A, Helmerhorst TJ, van Leeuwen JP, Pols HA. Estrogen receptor polymorphism predicts the onset of natural and surgical menopause. J Clin Endocrinol Metab 1999; 84:3146-3150.

55. Ioannidis JP, Stavrou I, Trikalinos TA, Zois C, Brandi ML, Gennari L, Albagha O, Ralston SH, Tsatsoulis A. Association of polymorphisms of the estrogen receptor alpha gene with bone mineral density and fracture risk in women: a meta-analysis. J Bone Miner Res 2002; 17:2048-2060.

56. Ioannidis JP, Ralston SH, Bennett ST, Brandi ML, Grinberg D, Karassa FB, et al; GENOMOS Study. Differential genetic effects of ESR1 gene polymorphisms on osteoporosis outcomes. JAMA 2004; 292:2105-2114.

57. Dick IM, Devine A, Prince RL. Association of an aromatase TTTA repeat polymorphism with circulating estrogen, bone structure and biochemistry in older women. Am J Physiol Endocrinol Metab 2004; Epub ahead of print.

58. Gennari L, Masi L, Merlotti D, Picariello L, Falchetti A, Tanini A, Mavilia C, Del Monte F, Gonnelli S, Lucani B, Gennari C, Brandi ML. A polymorphic CYP19 TTTA repeat influences aromatase activity and estrogen levels in elderly men: effects on bone metabolism. J Clin Endocrinol Metab 2004; 89:2803-2810.

59. Andrew T, Mak YT, Reed P, MacGregor AJ, Spector TD. Linkage and association for bone mineral density and heel ultrasound measurements with a simple tandem repeat polymorphism near the osteocalcin gene in female dizygotic twins. Osteoporos Int 2002; 13:745-754.

60. Uitterlinden AG, Weel AE, Burger H, Fang Y, van Duijn CM, Hofman A, van Leeuwen JP, Pols HA. Interaction between the vitamin D receptor gene and collagen type I alpha 1 gene in susceptibility for fracture. J Bone Miner Res 2001; 16:379-385.

61. Tofteng CL, Kindmark A, Brandstrom H, Abrahamsen B, Petersen S, Stiger F, Stilgren LS, Jensen JE, Vestergaard P, Langdahl BL, Mosekilde L. Danish Osteoporosis Prevention Study. Polymorphisms in the CYP19 and AR genes – relation to bone mass and longitudinal bone changes in postmenopausal women with or without hormone replacement therapy: The Danish Osteoporosis Prevention Study. Calcif Tissue Int 2004; 74:25-34.

62. Mak YT, Hampson G, Beresford JN, Spector TD. Variations in genome-wide gene expression in identical twins – a study of primary osteoblast-like culture from

female twins discordant for osteoporosis. BMC Genetics 2004; 5:14.

63. Reneland RH, Mah S, Kammerer S, Hoyal CR, Marnellos G, Wilson SG, Sambrook PN, Spector TD, Nelson MR, Braun A. Association between a variation in the phosphodiesterase 4D gene and bone mineral density. BMC Med Genet Genetics 2005; 7:6-9.

64. Spector TD, MacGregor AJ. Risk factors for osteoarthritis: genetics. Osteoarthritis Cartilage 2004; 12(Suppl.A):S39-S44.

65. Valdes AM, Hart DJ, Jones KA, Surdulescu G, Swarbrick P, Doyle DV, Schafer AJ, Spector TD. Association study of candidate genes for the prevalence and progression of knee osteoarthritis. Arthritis Rheum 2004; 50:2497-2507.

66. Valdes AM, Hassett G, Hart DJ, Spector TD. Radiographic progression of lumbar spine disc degeneration is influenced by variation at inflammatory genes: a candidate SNP association study in the Chingford cohort. Spine 2005; 30:2445-2451.